
Distinct regulation of hippocampal neuroplasticity and ciliary genes by corticosteroid receptors



Supplementary Fig. 1: Plasma corticosterone (CORT) levels under baseline conditions and after stress as well as after MR/GR antagonist treatments. Plasma CORT levels (ng/ml; mean ± SEM, n=5-12 rats; dots for number per group) from rats killed under early morning (BLAM) or late afternoon (BLPM) baseline conditions or at different times after the start of FS (15 min, 25 °C water), as indicated in the graphs. Each graph represents the plasma levels in rats killed for the original MR/GR ChIP-Seq (a), RNA-Seq (b) experiments, validation ChIP-qPCR (c) or RNA-qPCR (d), or receptor antagonist ChIP-qPCR (e) of RNA-qPCR (f, g) experiments. Statistical analysis: (a) Oneway ANOVA: F(2.33)=85.07, p<0.0001; (b) Oneway ANOVA: F(6.56)=185.9, P<0.0001; (c) Two-way ANOVA: Effect of stress: F(1,26)=244.0, p<0.0001; Effect of AM/PM: F(1,26)=34.73, P<0.0001; Interaction: F(1,26)=5.658, p=0.0250; (d) Two-way ANOVA: Effect of stress: F(1,28)0.7955, p=0.3800; Effect of AM/PM: F(1,28)=27.62, p<0.0001; Interaction: F(1,28)=13.27, p=0.0011; (e) Two-way ANOVA: Effect of stress: F(1,38)=375.0, p<0.0001; Effect of antagonist: F(2,38)=3.916, p=0.0284; Interaction: F(2,38)=1.659, p=0.2037; (f) Two-way ANOVA: Effect of stress: F(1.20)=29.67, p<0.0001; Effect of antagonist: F(1.20)=0.6154, p=0.4419; Interaction: F(1.20)=2.154, p=0.1578; (g) Two-way ANOVA: Effect of stress: F(1,27)=26.71, p<0.0001; Effect of antagonist: F(1,27)=14.59, p=0.0007; Interaction: F(1,27)=01792, p=0.8945; post-hoc Dunnett's test (a, b) or Bonferroni test (c-q): *, p < 0.05 compared with respective baseline (BLAM/BL) condition; \$, p < 0.05 compared with respective AM (c, d) or vehicle (e, f, g) condition. Source data are provided in the Source Data File.

Supplementary Figure 2

Overview of the distribution of MR and GR peaks across all chromosomes for each of the


four independent replicates and all physiological conditions studied.

You will find these distributions in the next 24 pages.


Legend:

EXPERIMENTAL GROUP	SAMPLES	INFORMATION RE EXPERIMENTAL GROUP		
Baseline AM (BLAM)	A, D, G, P	Rats killed under baseline (non-stress) conditions in the early morning (AM)		
FS30	B, E, K, Q	Rats killed 30 min after forced swimming (FS)		
Baseline PM (BLPM)	C, F, I, R	Rats killed under baseline conditions in the early evening (PM)		


Replicate A-GR-baselineAM:



Replicate A-MR-baselineAM:




Replicate B-GR-fs30:



Replicate B-MR-fs30:

Ch	IP Peaks over Chromosomes	
3000 - 2000 - 1000 - 800 - 600 - 400 - 200 -		1
600 - 400 - 200 -	البعاد بمعدد بالمان المالية المراجعين المتعاد المعادية والمعالية	2
2000 15588 15588	المستطعات والمستعلم والمستعد المستعد	3
750 500 250	and a construction of the second s	4
1000 1 750 - 500 - 250 -	ran a sa an	5
750 250 1000 750 250 250 250 250 250 1000 250 250 1000 250 250 250 250 250 250 250 250 250		6
1990 1990 500		7
2501 1500 - 1000 - 500 -	at and a construction of a construction of the data of	
0,1	an a'	9
900 - 600 - 300 -	a anna a' bana ta anna a' a	H
1500 1000 500	e e e e e e e e e e e e e e e e e e e	10
600 - 400 - 200 -	بتسايير باستريتها الم	11
3000 - 2000 - 1000 - 600 1		12
400 - 200 -	I	13
600 - 400 -	يرو والمار الماري ا	14
		15
900 - 600 - 300 -		16
300 - 200 -		17
300 - 200 - 100 - 750 - 500 - 250 -	, at the first of the second state of the seco	18
256] 588:1	(1) Description of the second se Second second sec second second sec	H
788j 5000-1	ja su ku	19
160 T	align the second s	20
160 120 80 40		x
	0e+00 1e+08 2e+08 Chromosome Size (bp)	


Replicate C-GR-baselinePM:




Replicate C-MR-baselinePM:

ChIP Peaks over Chromosomes				
	1			
1998]	2			
100] Talahatan ang manang ma Bang manang man Bang manang ma				
	4			
المحمد المعالية المحمد الم	5			
750-1 200-10	6			
750-1 250-2 0 d	7			
1500-1 1000-1 500-	8			
2001 1200 2002 2002 2003 2004 2004 2005 2005 2005 2005 2005 2005	9			
	10			
500 j maradadakan wakan kutuk kutuk ang aka ka kasu 1200 j 1200 j 1200 j	11			
	12			
1000- 500- 600	13			
	14			
	15			
	16			
300 ⁻¹	17			
1998] הארבו ולהאות הייני ביאה אולה הארביים. 1998:1	18			
1988] 289] I.J. III. a. I				
	19			
	20			
	x			
0 ce +o0 1e +o8 2e +o8 Chromosome Size (bp)				

Replicate D-GR-baselineAM:




Replicate D-MR-baselineAM:




Replicate E-GR-fs30:

C	hIP Peaks over Chromosomes	_
8000 6000 4000 2000		1
1888		2
4000 1 3000 1 2000 1 1000 1	and a second second second second second second second	з
1258		4
250 250 2000 2000 1000		5
3588 1888		6
3000 2000 1000 0	in a set la seconda de la s Internación de la seconda d	7
1000 - 3000 - 2000 - 1000 -	n an	8
	1. A second s	H
1000 7500 2500 2500	а .ж.б. ва стала страна в на страна стран	9
6000 - 4000 - 2000 - 4000 1	and an and a second case. The descent processes the second s	10
4000 - 3000 - 2000 - 1000 - 3000 -	a juan ana ana ana ana ana ana ana ana ana	11
3000 2000 1000		12
		13
800 600 400 200	سانت بالأبل اين	14
1000 - 500 -		15
0 1000 500 250 800 400 1200 1200 1200 400 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 10		16
800 600 400		17
2001 1600 1200 800	, de la strata de la stratada en la companya de la c	18
12581	الدية معادية معادية المتعادية العالمية معادية المتعادية المتعادية المتعادية المتعادية المتعادية المتعادية المت أجلال ا	19
598 15000 12000	r tanın azərba Aldır T	H
10000 1000000	معالمی در ان	20
1881		×
	Chromosome Size (bp)	

Replicate E-MR-fs30:




Replicate F-GR-baselinePM:




Replicate F-MR-baselinePM:

ChIP Peaks over Chromosomes • • 2 und h. ulli i 1.1.1 1 1 I In ١, ılı. . . ill. 1 L ıl J. 10.51 .11 з т II. J . .t ر الا المانية ال 1.14 1.1.1 . . Ŀ. . . I . .. 5 وببابر الجدياء a. d 6 ъ.l. ավես դ . 1 1998 1998 298 7 يباسه للبالسال 8 1200 800 400 ىلى س al s ь. 4. 9 10 11 а ս. հես ľ ها، بالد . . j, Ι. 14 13 المانية براطة տե. հո 14 adh. I ъđ 15 J. 16 17 18 19 ال. I. 1.14 ı. սեե Ι. 20 .1.. х 100-50-0-1e+08 2e+08 0e+00 Chromosome Size (bp)


Replicate G-GR-baselineAM:



Replicate G-MR-baselineAM:



Replicate I-GR-baselinePM:



Replicate I-MR-baselinePM:

Ch	nIP Peaks over Chromosomes	
4000 3000 - 2000 - 1000 - 600 - 400 -		1
600 400	in a construction of the second se	2
200- 0 1500-	, persithMutan tertinistication (and shiru) and als - BUbian and subshaha also ante attrict hit hutan. Γ	H
1000 - 500 - 0	والمانية والمتعاملة والمتعاملة والمتعادية والمتعادية والمتعادية والمتعاملة والمتعادية والمتعاملة والمتعادية والم	3
900 - 600 - 300 - 0		4
1000 - 500 -	يتماني التستقانية والمتناقلة وأصلين ومنتقر والتروي والمتحر والمتحر والتنقير والمتحر	5
1258 258	مالالا مادة مدينات مدينا والمعالية مناها والمناه والمناها والمناها والمناها والمناها والمناها والمناه	6
1000 - 500 - 2000 -	ليتاريك الماليل المراجع المحاد	7
1500 - 1000 - 500 -	الاستان المتعلقات المعلمات المتعادي المتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعادية	8
1000 - 500 -	a a marina a hara a shata a marina ar a a	9
2000 1 1500 1 1500 1		10
1990 1 1990 1		H
1000 750 500 250	a see allede us a saarda ele ha	11
3000 - 2000 - 1000 -		12
3000 2000 100 1000 1	la hale - neede -	13
800 600		14
200 j \$88 i	Tallacia - Esala - Constala a contra	
1883	Այս հատկես հետ համան համալ անկ հետ հետ հետ	15
750 500 250	براها المراجع ا	16
		17
1081 12201	na katulta ta ta ta ta ta katulta katu	
1000- 750- 250- 250-	lation of the second	18
600 1 400 1 200 1	. m a shows but stall	19
200] 8000] 6000] 4000 ; 2000]		20
200 - 100 -		X
1001		
	Chromosome Size (bp)	


Replicate K-GR-fs30:

C	hIP Peaks over Chromosomes	
8000 + 6000 + 4000 + 2000 -	and the second	1
3588 1 1888 1		2
3001 3000	ال المانية في منه به المانية الله المانية المنه ال ا	3
78883 1.500 f	المنافعة المنتخبة المنتخبة المنتخبة المنتخبة المنتخبة المنتخبة المنتخبة المنتخبة المنتخبة المنافعة المنافعة الم	H
1500 1000 500	متعا يتعارف سالا والمعاد والمطبورة والأسلام والمتعادة	4
3000 - 2000 - 1000 - 0	en e	5
3000 1 2000 - 1000 -	a and a faile a faile a faile a substance of the set	6
4000 1 3000 1 2000 1 1000 1	. dr	7
4888 - 1888 - 1888 -	an an an taona an an taona an An taona an t	
1008j	د بیش د. د. د. د. ماد ساله ساله ساله ساله ساله ساله ساله ساله	9
750 - 500 - 250 - 6000 -	a sakalahanan kabutuk sakala sala sala sala sa ka	
6000 - 4000 - 2000 -	يعد الجار مدينة المانية	10
4000 1 3000 1 2000 1	a and the second states of the	11
3588 1588 1588		12
1500 - 1000 - 500 -		13
750 - 500 - 250 -		14
250 j 200 i	palitana parte har er et taller et en er	H
900 600 300 1500	Hautstal data waan ar di	15
1500 1000 500 0	المحاد والمحالف المحالية المحالية والمحالية والمح	16
1000 - 500 -	. n. lla al mar net internet dat	17
1600 1 1200 1 800 1 400 1	al a success a successful	18
1000-		19
16000 1 12000 1 8000 1 4000 1	laith a chuir a chuidheadh I	20
4000 - 300 -	alla	
300 1 200 1 100 1		×
	Chromosome Size (bp)	


Replicate K-MR-fs30:

ChIP Peaks over Chromosomes	
1881	1
2003 2004 - C. C. Barris, C. B. C. Barris, C. B. C. Barris, C. C. C. Barris, C. C. B	2
1000 1000 1000 1000 1000 1000 1000 100	3
1200 التي المراجع	4
1200 400 300 1000 1000	5
1000-] a.d.a.taht.Ja	6
¹ 900- ³ 000- 2000- 2000- 100-	8
Office and the state of the sta	9
1500-1 1000-1 500-1	10
1988] 1988] 1988] 1988] 1988] 1999]	11
³⁰⁰ 3, a thatairt r, ideata dh. ³⁰⁰ 3, a thatairt ann ionna	12
1000-	13
	14
المتعادية المتعادية والمتعادية والمتعادية والمتعادية والمتعادية والمتعاد المتعاد المتعاد المتعاد المتعاد المتعا	15
	16
400- 200- 0	17
1500 - 1000 - 500 - 1 II	18
	19
	20
	x
0e+00 1e+08 2e+08 Chromosome Size (bp)	

Replicate P-GR-baselineAM:



Replicate P-MR-baselineAM:




Replicate Q-GR-fs30:

	hIP Peaks over Chromosomes	
8000 1 6000 1 4000 1 2000 1		1
2000 -	ا ما السامية المانية ا ا	2
1000	المراجع المستقد والمستقد والمستقد والمستقد والمستقد والمستعد والمستقد والمستقد والمستقد والمستقد والم	Ľ
6000 1 4000 - 2000 -	المراجع والمراجع	з
1258 1258 2580		4
250 J 3000 J	real and a solution of an E. I. della cate to advall. We had also	H
3000 - 2000 - 1000 -	المستقدمة والمستقدية المرعد والمستقد المستقد المستقد المستقد والمستقدة والمستقدة والمستقدة والمستقدة والمستقد وال	5
3000 - 2000 - 1000 - 0	a second de la contra	6
3000 - 2000 - 1000 -		7
0,	an an annana an an lana anna an annadhaltan bha. T	H
1200	المتعامية والمتعامية وال	8
4000 1200 1900 1900 900 900 900 900	e adole man lange liting allow here in a	9
6000 - 4000 - 2000 -		10
4000 -	and a second and a second production of the second se	H
1000		11
2000 - 1000 -		12
		13
1988] 750-1	· · · In - · · · · · · · · · · · · · · · · · ·	H
500 - 250 -	المتعادين والمستعدية والمستعدين والمتعادية وال	14
750 500 250 1250 1250 1200 250 1600 1200 250 1600 1200 1200 1200 250	de de sal status de ser au an	15
1600 1 1200 1 800 1	h l	16
400j 1000-	Alatinatha i contra and contra and a second se	H
500	ali ali calle de de la calendaria de calendaria de la calendaria	17
1600 1 1200 1 800 1 400 1	I a maa waa ka maa waa ka ma	18
1500 - 1000 - 500 -		19
20000	ter ar e tara a dalah dalah ing serien a dalah ing serien ar	H
20000 - 15000 - 10000 - 5000 -	alar - to the state	20
300 1 200 1 100 1	a huda a shatta a	x
0	Ce+00 1e+08 2e+08 Chromosome Size (bp)	

Replicate Q-MR-fs30:


ChIP Peaks over Chromosomes				
3000 - 2000 - 1000 -	- consistence in the second state of the second	1		
	การกรุงการสายสาย และการสาย เป็นการการสาย และสายสายการการสายการการสายสายสายสายสายสายสายสาย สายสายสายสายสายสายสาย	2		
3000 1 2000 1 1000 1	na bilana an	з		
600 - 400 - 200 -	المتعادية المعالية والمتعالية والمتعادية والمتعالية والمتعالية والمتعالية والمتعادية والمتعادية	4		
1500 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 900 - 900 - 900 - 900 - 900 -	ليعتقد الاستعمام ألماست فالتحالي التركي التركي المراجع المراجع المراجع المراجع المراجع المراجع المراجع المراجع	5		
1000 1 250 1 1200 1	andar and here was an effect of the construction of the second second second second second second second second	6		
900 - 500 - 300 -	and a second	7		
1888]		8		
2000 1	surrandolserset indus a constraint administration of the second second second second second second second second	9		
2000 1500 1000 500 800 400 200 400 200 1000 1000 1000	a and an a substance block and a high and have	10		
4000 4000 40000	en en en pladar e e en en entre dat eller des	11		
0,4	and the second	12		
2000 1000 1000 500	·····	13		
750 500 250 508	المانية من منها المانية الماني المانية	14		
\$88 \$88 1990	. Ha	15		
1200 1200 400 500	adada a an	16		
4081 12581	. ա. Աստոտա հայ ու ու ու ու ու ու հակարություններին հետ	17		
1250 2590 2590 2590 2590	and the end of the second at	18		
400 200 6000 4000 4000	n an	19		
		20		
150 100 50 100	i hi i li hi i li li i li i li i li i l	×		
100 - 50 - 0	0e+00 1e+08 2e+08	Ŷ		
	Chromosome Size (bp)			

Replicate R-GR-baselinePM:



Replicate R-MR-baselinePM:


CI	hIP Peaks over Chromosomes	
6000 1 4000 - 2000 -		1
600 - 400 - 200 -	an an such Minimute state at the set of the	2
1888	متنابع المطفر وتسليله والانتصالية والمتعاد متنا بالمراجعة المراجع المراجع المراجع المتعار والمتعار والمتعار	з
1000 - 500 - 0	the second	4
1888		5
1000 - 500 -	and an analysis and a second	6
1000 - 500 - 1600 - 1200 - 400 -	مراجعة المتعادية والمتعادية والمتعادية المتعادية المتعادية والمتعادية والمتعادية والمتعادية والمتعادية	7
1888]	والقب والمحافظ	8
1600 1200 1200 400	المراجع ا	9
1888	والمراجع المراجع المراجع والمراجع	10
1500	and a second	11
鸝	an a bir dama mana a mada manan	12
1000 - 500 -	· · · · · · · · · · · · · · · · · · ·	13
	and the second of the second	14
800 400 200	alle a laste sta I , la anchen ar 2000 a 1960 a 2010 a 2010 a 2010 a 2010 a	15
1500 1000 - 500 -	ulthe contact of the second second	16
188 1883	as the call all calls. The contract of the field of the contract of	17
1000-	and the second case on the second case of the second s	18
800 400 200	Les Marine Marine Martine Martine Carlos and Carlo	19
12588 2588		20
1200 1200 400		МТ
1000- 500- 8000- 8000- 100000- 100000- 100000- 100000- 10000- 10000- 10000- 10000- 10000- 100- 1000- 1	a latin a construction of the later second	×
60 + 40 - 20 -		Y
	0e+00 1e+08 2e+08 Chromosome Size (bp)	






Supplementary Fig. 3: Principal component analysis (PCA) of the top-1000 most variable genes based on intronic read data. This figure shows all PCA plots including the ones presented in Figure 3 to allow comparison of all plots within one figure. Limited clustering is evident in FS120 vs BLAM, FS180 vs BLAM, FS360 vs BLAM supporting the reduction in genes responding significantly to stress at these Time points compared with other comparisons (BLPM vs BLAM, FS30 vs BLAM, FS60 vs BLAM; this figure and Fig. 3 a-c).


Group • BL AM • FS360




Supplementary Fig. 4: Principal component analysis (PCA) of the top 1000 most variable genes based on exonic read data. Clustering of samples by group is largely absent along either eigenvector (PC1 or PC2) indicating that much of the variance in the data cannot be explained by group differences.



Supplementary Fig. 5: Spearman rank correlation analysis between the fold-change in receptor binding and the associated fold-change in RNA expression under stress and circadian changes. **a**, Correlation between MR binding and exRNA under stress conditions; **b**, Correlation between MR binding and exRNA under stress conditions; **b**, Correlation between MR binding and exRNA under circadian conditions; **c**, Correlation between GR binding and exRNA under stress conditions. The results of the correlation analysis are depicted in the subfigures. For more information and correlation statistical analyses, see text of the Results section. Source data are provided in the Source Data File.




Supplementary Fig. 6: Gene maps showing location of MR and GR binding peaks in the rat genome based on our MR and GR ChIP-Seq data. An MR binding peak is situated within the promoter of the cilia-related genes *Cep41* and *Ift57*. The synaptic plasticity-related genes *Ptk2b* and *Camk2a* contain multiple stress- and circadian-responsive MR and GR peaks. The locations depicted in red are the ones targeted by primers designed against MR and/or GR binding regions within these genes concerning which data are shown in Suppl. Figs 7 & 9. Gene tracks were adapted from the Rnor_6.0 assembly (genome.ucsc.edu/)




The legend of Supplementary Figure 7 is on the next page.

Supplementary Fig. 7: Validation of ChIP-Seq and RNA-Seq findings in an independent cohort of rats killed under baseline (BL) conditions or 30 min (for ChIP) or 60 min (for hnRNA) after exposure to FS performed during the early morning circadian trough (AM) or late afternoon circadian peak (PM). ChIP-qPCR and RNA analysis were conducted on the genes Ptk2b (a, MR ChIP; b, GR ChIP; c, hnRNA), Camk2a (d, MR ChIP; e, GR ChIP; f, hnRNA), Hif3a (g, MR ChIP; h, GR ChIP; i, hnRNA), Ift57 (j, MR ChIP; k, GR ChIP; I, hnRNA) and Cep41 (m, MR ChIP; n, GR ChIP; o, hnRNA). The MR and GR ChIP graphs show mean enrichment ((Bound/Input (B/I); mean ± SEM; n=4). The hnRNA graphs show the results from hnRNA RT-qPCR analyses (mean ± SEM, n=8-9). Statistical analysis: Twoway ANOVA: (a) MR ChIP - Ptk2b; effect of AM/PM: F(1, 12)=0.3773, p=0.55; effect of Group: F(1, 12)=0.4682, p=0.51; interaction AM/PM x Group: F(1, 12)=8.728, p=0.01 (b) GR ChIP – Ptk2b; effect of AM/PM: F(1, 12)=29.40, p<0.001; effect of Group: F(1, 12)=54.81, p<0.001; interaction AM/PM x Group: F(1, 12)=27.71, p<0.001 (c) Ptk2b hnRNA; effect of AM/PM: F(1, 28)=9.153, p=0.0053; effect of Group: F(1, 28)=20.76, p<0.0001; interaction AM/PM x Group: F(1, 28)=6.897, p<0.0138 (d) MR ChIP - Camk2a; effect of AM/PM: F(1, 12)=5.040, p=0.0444; effect of Group: F(1, 12)=4.834, p=0.0483; interaction AM/PM x Group: F(1, 12)=10.91, p=0.0063 (e) GR ChIP - Camk2a; effect of AM/PM: F(1, 12)=22.93, p=0.0004; effect of Group: F(1, 12)=78.97, p<0.0001; interaction AM/PM x Group: F(1, 12)=7.636, p=0.0172 (f) Camk2a hnRNA; effect of AM/PM: F(1, 28)=14.61, p=0.0007; effect of Group: F(1, 28)=80.53, p=0.0084; interaction AM/PM x Group: F(1, 28)=0.6296, p<0.4342 (g) MR ChIP – Hif3a; effect of AM/PM: F(1, 12)=26.45, p=0.0002; effect of Group: F(1, 12)=4.592, p=0.0533; interaction AM/PM x Group: F(1, 12)=12.56, p=0.004 (h) GR ChIP -Hif3a; effect of AM/PM: F(1, 12)=23.11, p=0.0004; effect of Group: F(1, 12)=10.05, p=0.0081; interaction AM/PM x Group: F(1, 12)=0.6184, p=0.4469 (i) Hif3a hnRNA; effect of AM/PM: F(1, 28)=139.2, p<0.0001; effect of Group: F(1, 28)=79.43, p<0.0001; interaction AM/PM x Group: F(1, 28)=6.665, p<0.0154 (j) MR ChIP - Ift57; effect of AM/PM: F(1, 12)=0.2445, p=0.6299; effect of Group: F(1, 12)=0.07847, p=0.7842; interaction AM/PM x Group: F(1, 12)=1.254, p=0.2847 (k) GR ChIP – Ift57; effect of AM/PM: F(1, 12)=11.97, p=0.0047; effect of Group: F(1, 12)=0.7770, p=0.3954; interaction AM/PM x Group: F(1, 12)=0.9073, p=0.3596 (I) Ift57 hnRNA; effect of AM/PM: F(1, 28)=4.457, p=0.0438; effect of Group: F(1, 28)=0.2571, p=0.6161; interaction AM/PM x Group: F(1, 28)=0.2566, p<0.06164 (m) MR ChIP - Cep41; effect of AM/PM: F(1, 12)=0.004168, p=0.9496; effect of Group: F(1, 12)=0.09523, p=0.7629; interaction AM/PM x Group: F(1, 12)=0.7050, p=0.4175 (n) GR ChIP – Ift57; effect of AM/PM: F(1, 12)=11.22, p=0.0058; effect of Group: F(1, 12)=1.354, p=0.2672; interaction AM/PM x Group: F(1, 12)=2.903, p=0.1141 (o) Ift57 hnRNA; effect of AM/PM: F(1, 28)=0.2079, p=0.6519; effect of Group: F(1, 28)=0.2442, p=0.6250; interaction AM/PM x Group: F(1, 28)=2.078, p=0.1606. Post-hoc Bonferroni multiple comparisons test: *, p<0.05, compared with respective baseline group; \$, p<0.05, compared with respective AM group. Source data are provided in the Source Data File.




Supplementary Fig. 8. Demonstration of specific immunoreactivity of antibodies used in the validation experiments by Western blotting and non-specific IgG ChIP. Hippocampal whole-cell extracts from male Wistar rats were subjected to SDS-PAGE, electrophoretically transferred to PVDF membrane and incubated with antibody to confirm antibody specificity (n=1, as confirmation only). According to UniProt, GR has two protein isoforms (A, ~87 kDa, P06536-1; B ~84 kDa, P06536-2), MR has three possible isoforms (1, ~106 kDa, P22199-1; 2, ~107 kDa, P22199-2; 3, ~86 kDa P22199-3) and RFX3 sequence remains unreviewed. a, anti-GR antibody (rabbit polyclonal, Proteintech, 24050-1-AP), one band >95 kDa marker consistent with the reported GR band (~94-97 kDa, Proteintech); b, anti-MR antibody (rabbit polyclonal, Abcam, ab64457), predominant bands at >95 kDa consistent with the reported MR band (~100 kDa, Abcam) and 45 kDa. All bands blocked in the presence of blocking peptide ab74464 confirming MR specificity; c, anti-MR antibody (rabbit polyclonal, Abcam, ab97834), one band present ~85 kDa consistent with MR isoform 3 (predicted ~86 kDa, P22199-3 UniProt); d, anti-RFX3 antibody (rabbit polyclonal, Proteintech, 14784-1-AP), one band present ~70 kDa consistence with the reported RFX3 band (70-79 kDa, Proteintech). Assessment of non-specific IgG binding in hippocampal chromatin of BL and FS30 male Wistar rats, as in Suppl. Fig. 7) using Abcam IgG (ab171870) and Proteintech IgG (30000-0-AP) at Cep41 (e, f) and Ptk2b (g, h). Enrichment (Mean ± SEM, n=3-4 biologically independent repeats; see dots for exact number) was <1 in all cases with no significant differences between groups. Statistical analysis: Two-way ANOVA: (e) Abcam IgG ChIP – Cep41; effect of Group: F(1, 11)=1.273, p=0.2832; effect of AM/PM: F(1, 11)=0.1372, p=0.7181; interaction Group x AM/PM: F(1, 11)=0.1823, p=0.6776. (f) Proteintech IgG ChIP - Cep41; effect of Group: F(1, 12)=0.6452, p=0.4374; effect of AM/PM: F(1, 12)=0.3582, p=0.5606; interaction Group x AM/PM: F(1, 12)=1.250, p=0.2854. (g) Abcam IgG ChIP – Ptk2b; effect of Group: F(1, 11)=0.4162, p=0.5321; effect of AM/PM: F(1, 11)=0.02765, p=0.8710; interaction Group x AM/PM: F(1, 11)=0.1810, p=0.6787. (h) Proteintech IgG ChIP -Ptk2b; effect of Group: F(1, 12)=0.8787, p=0.3670; effect of AM/PM: F(1, 12)=1.048, p=0.3261; interaction Group x AM/PM: F(1, 12)=0.4542, p=0.5131. Source data are provided as a Source Data file.




The legend of Supplementary Figure 9 is on the next page.

Supplementary Fig. 9: Effect of MR and GR antagonists on hippocampal MR and GR binding and RNA transcription in response to stress or circadian changes. The MR antagonist spironolactone (Spiro, 50 mg/kg), GR antagonist RU486 (RU, 100 mg/kg) or vehicle (50% condensed milk) was administered to rats via voluntary dosing (1 ml/rat, see Methods for details). Rats were subsequently killed under baseline (BL) conditions or 30 min (for ChIP; FS30) or 60 min (for hnRNA; FS60) after exposure to FS. ChIP-qPCR and RNA analysis were conducted on the genes Ptk2b (a, MR ChIP; b, GR ChIP; c & d, hnRNA), Camk2a (e, MR ChIP; f, GR ChIP; g & h, hnRNA), Hif3a (i, MR ChIP; j, GR ChIP; k & I hnRNA), Ift57 (m, MR ChIP; n & o, hnRNA) and Cep41 (p, MR ChIP; q & r, hnRNA). GR ChIP samples were not analysed for lft57 and Cep41 due to poor GR enrichment levels within these genes shown previously (Suppl. Fig. 7k & 7n). The MR and GR ChIP graphs show mean enrichment ((Bound/Input (B/I); mean ± SEM; n=4 biologically independent replicates). The hnRNA graphs show the results from hnRNA RT-qPCR analyses (mean ± SEM, n=6-8 biologically independent replicates; see dots in graphs for exact n of each experimental group). Statistical analysis: Two-way ANOVA: (a) MR ChIP - Ptk2b; effect of Antagonist: F(2,18)=1.823, p=0.1898; effect of Group: F(1,18)=16.65, p=0.0007; interaction Antagonist x Group: F(2,18)=1.926, p=0.1746 (b) GR ChIP – Ptk2b; effect of Antagonist: F(2,18)=1.398, p=0.1415; effect of Group: F(1,18)=33.24, p<0.0001; interaction Antagonist x Group: F(2,18)=2.184, p=0.1415 (c) Ptk2b hnRNA – Spiro; effect of Antagonist: F(1,20)=0.2319, p=0.6353; effect of Group: F(1.20)=26.68, p<0.0001; interaction Antagonist x Group: F(1,20)=1.757e⁻⁵, p<0.9967 (d) Ptk2b hnRNA – RU; effect of Antagonist: F(1,28)=0.3550, p=0.5561; effect of Group: F(1,28)=46.07, p<0.0001; interaction Antagonist x Group: F(1,28)=0.3800, p=0.5426 (e) MR ChIP - Camk2a; effect of Antagonist: F(2,18)=0.4317, p=0.6560; effect of Group: F(1,18)=21.95, p=0.0002; interaction Antagonist x Group: F(2,18)=0.8952, p=0.4260 (f) GR ChIP – Camk2a; effect of Antagonist: F(2,18)=2.927, p=0.0793; effect of Group: F(1.18)=45.95, p<0.0001; interaction Antagonist x Group: F(2.18)=3.297. p=0.0603 (g) Camk2a hnRNA - Spiro; effect of Antagonist: F(1,20)=0.4206, p=0.5240; effect of Group: F(1,20)=17.29, p=0.0005; interaction Antagonist x Group: F(1,20)=0.2894, p=0.5965 (h) Camk2a hnRNA – RU; effect of Antagonist: F(1,28)=0.3139, p=0.5798; effect of Group: F(1,28)=22.75, p<0.0001; interaction Antagonist x Group: F(1,28)=0.4770, p=0.4955 (i) MR ChIP -Hif3a; effect of Antagonist: F(2,18)=4.401, p=0.0278; effect of Group: F(1,18)=50.49, p<0.0001; interaction Antagonist x Group: F(2,18)=5.442, p=0.0142 (j) GR ChIP – Hif3a; effect of Antagonist: F(2,18)=1.368, p=0.2799; effect of Group: F(1,18)=68.54, p<0.0001; interaction Antagonist x Group: F(2,18)=9.440, p=0.0016 (k) Hif3a hnRNA – Spiro; effect of Antagonist: F(1,20)=13.15, p=0.0017; effect of Group: F(1.20)=168.0, p<0.0001; interaction Antagonist x Group: F(1,20)=6.067, p=0.0230 (I) Hif3a hnRNA – RU; effect of Antagonist: F(1,28)=1.208, p=0.2810; effect of Group: F(1,28)=28.03, p<0.0001; interaction Antagonist x Group: F(1,28)=7.839, p=0.0092 (m) MR ChIP – Ift57; effect of Antagonist: F(2,18)=0.8694, p=0.4361; effect of Group: F(1,18)=0.0001365, p=0.9709; interaction Antagonist x Group: F(2,18)=0.5416, p=0.5910 (n) Ift57 hnRNA – Spiro; effect of Antagonist: F(1,20)=8.842, p=0.0075; effect of Group: F(1,20)=0.7432, p=0.3988; interaction Antagonist x Group: F(1,20)=0.3114, p=0.5830 (o) Ift57 hnRNA - RU; effect of Antagonist: F(1,28)=0.4470, p=0.5092; effect of Group: F(1,28)=0.2142, p=0.6471; interaction Antagonist x Group: F(1,28)=1.120, p=0.2990 (p) MR ChIP - Cep41; effect of Antagonist: F(2,18)=0.03626, p=0.9645; effect of Group: F(1,18)=1.701, p=0.2086; interaction Antagonist x Group: F(2,18)=0.9900, p=0.3909 (q) Cep41 hnRNA – Spiro; effect of Antagonist: F(1,20)=1.797, p=0.1951; effect of Group: F(1,20)=2.570, p=0.1246; interaction Antagonist x Group: F(1,20)=0.05927, p=0.8101 (r) Cep41 hnRNA – RU; effect of Antagonist: F(1,28)=7.079, p=0.0128; effect of Group: F(1,28)=0.3142, p=0.5796; interaction Antagonist x Group: F(1,28)=0.3676, p=0.2990. Post-hoc Bonferroni multiple comparisons test: *, p<0.05 compared with respective BL group; \$, P<0.05 compared with respective vehicle group. Source data are provided in the Source Data File.






MR Nuclear Staining



Supplementary Fig. 10. Spironolactone (Spiro) treatment results in decreased nuclear localization of MR in hfNPCs. From the start of neuronal differentiation, hfNPCs were treated for 1 week with 0, 100 nM or 10 μ M Spiro after which cells were processed for MR immunocytochemistry (**a**; scale bar = 50 μ m; see Methods for details). **b**. The integrated nuclear staining density of MR immunoreactivity was assessed using ImageJ with the plugin 'Analyze particles'. Data are expressed as Integrated Nuclear Density (Mean ± SEM, n=6 biologically independent replicates per condition). Oneway ANOVA: F(2,15)=40.02, p<0.0001; post-hoc Dunnett's test: **, p=0.0011; ****, p<0.0001. Source data are provided in the Source Data File.



Supplementary Fig. 11. Workflow of the bioinformatic analysis pipeline for our

ChIP-Seq data.

	Raw data	Alignment	QC metrics	Quantification	Differential Expression (DE)	Pathway analysis	
	RNAseq FASTQ files (37 RiboZero RNAseq samples)	Splice-aware aligner <i>(Hisat2)</i>	Picard tools (CollectRnaSeq Metrics and MarkDuplicates on alignment BAM)	Quantification to Exon feature GTF or Intron feature GTF and summarized to ENSEME gene IDS <i>(FeatureCounts with parameters</i> -M -p -Ofraction) Normalized read count for PCA and QC (base R)	normalization Step2. Estimate Dispersion and fit data to generalized linear models	Gene ontology enrichment analysis using DE genes (FDR <0.05) and with length bias correction (GOseq)	1
_	ixon feature GTF	Exc	n1	Exon2	Exon3	Ger	neA
	Full-length transcript GTF			Transcript1		Ger	۱eA
Intron feature GTF produced with Bedtools subtractBed		ed	Intro	n1 Intron2		Ger	neA

Supplementary Fig. 12. Workflow of the bioinformatic analysis pipeline for our RNA-

Seq data.

	MR p	beaks	GR peaks	
	Motif	% (n=1753)	Motif	% (n=1066)
	GRE	77	GRE	93
	ZNF	76	ZNF	74
All peaks	SP	74	SP	70
	KLF	70	KLF	68
	EGR	64	EWSR1-FLI1	44
	Motif	% (n=401)	Motif	% (n=74)
	SP	80	NR	65
Non-GRE	ZNF	76	STAT	62
containing	KLF	76	ZNF	51
peaks	EGR	74	PAX	49
	RFX	73	EWSR1-FLI1	48

Supplementary Table 1. FIMO analysis of transcription factor binding motifs within MR and GR binding peaks. The top 5 transcription factor binding motifs found in all MR and GR binding peaks are listed and confirm GRE as the predominant motif. In MR and GR binding peaks without a concensus GRE some variation in top 5 motifs present is observed (i.e. the RFX motif in non-GRE containing MR peaks and the NR, STAT and PAX motifs in non-GRE containing GR peaks).

Target	Gene ID	Accession number	Forward primer sequence (5' - 3')	Reverse primer sequence (5' - 3')	Probe sequence (FAM_5' - 3'_TAMRA)
gDNA	Camk2a	NM_012920	ATTCAGTGTTCCCTTCAACAAACA	CGCCAACCCAGCAGAAGT	TCCGGTTCTGAGGCCTTCTGTGTCCT
	Cep41	NM_001025770	GCCCTTGGCAACCATTGA	TCCCTGTAACCTCTCTTCCGATT	CGGCTTCTCGCTCTCCCTCGCT
	Hif3a	NM_001388512	CTCTCACCGCCTTGCACTAAT	GGGATGGGAGGGCTACAAA	CCACCCCGCACCCAGACTAAAA
	lft57	NM_001107093	CTTTGGTTGGCGAGAATTTAGAG	CCCTGTCGCCAACGTTACC	CCATGGTGACCGGCAGCCCT
	Ptk2b	NM_017318	CTTGTCCCCACTTCTGCTACCT	ACAGTGTGCTCTGCCTGATGA	CTCCCACTTCCTCTGTCTCATCTTGCCAA
hnRNA	B-actin	NM_031144	TGTATTCCTTTCTCTACAGATCATGTTTG	AGAGGCATACAGGGACAACACA	ACACCCCAGCCATGTACGTAGCCATC
	Camk2a	NM_012920	ACCTGCATTTCAGATCACCAGAA	ACACTGTTCCATGACCTCTCACA	ACGCGAGGCCCGCATCTGC
	Cep41	NM_001025770	CTCCGTGCTTGGAACCTTAACT	GCCTCTCGTCGTCATCGTACA	TCACAGAAAAATGCTCATGGCAAGATCATC
	Hif3a	NM_001388512	TGTCCCTGCAGTGACCCTTAC	GGAAGCGATACTGCCCTGTTAC	CCCCTCTCCCCAGTGCTGAGCA
	Hprt1	NM_012583	TGTGCTTGCAGACCAAATACTCTTA	CGTGGATCAAGACGAGACATTG	CCACTGAGTCACCTCCCCAATGCC
	lft57	NM_001107093	TGTGTGCTTATACCACTAGGATTGG	TCTCCTTTAGAGCAGATTCAATTCC	CACGTTGACCAAATGCACCAGCACA
	Ptk2b	NM_017318	TGACCTTTAACCCGCTCCAT	CGATGTGAGGGTGGTCAAGA	CCTCTCCCCCTCCTTCAGTGATCATGA
	Ywhaz	NM_013011	GGGCACATGTGTCCGATACTG	CACCCTAGGGACAGCTTACAACA	CGCGATTGGATCCCCCGGAAT

Supplementary Table 2. Primer/Probe sequences for ChIP (gDNA) and RNA (hnRNA) analysis. Primer and probe sets were designed using Primer Express 3.0.1 (Life Technologies Corp) and validated. All primer sets generated primer efficiencies of >90%.